Medtronic OmniaSecure™ defibrillation lead is the first lead of its kind to receive FDA approval for conduction system pacing

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, received U.S. Food and Drug Administration (FDA) approval for an expanded indication for the OmniaSecure™ defibrillation lead. Now ...
MassDevice

Medtronic wins expanded FDA approval for OmniaSecure for conduction pacing

Medtronic (NYSE: MDT) announced today that it received FDA approval for an expanded indication for its OmniaSecure defibrillation lead.

Medtronic plc: Medtronic OmniaSecure defibrillation lead is the first lead of its kind to receive FDA approval for conduction system pacing

Built for high reliability, world's only lumenless defibrillation lead approved for placement in the left bundle branch area GALWAY, Ireland, March 23, 2026 /PRNewswire/ -- Medtronic plc ...
Medical Device Network on MSN

Medtronic’s OmniaSecure defib lead nets another FDA approval

OmniaSecure is now the first defibrillation lead approved for placement in the left bundle branch.

Study identifies liver–metabolic disease as a key risk factor for heart failure in older adults with atrial fibrillation

Atrial fibrillation (AFib) is the most common cardiac arrhythmia worldwide and a major contributor to heart failure (HF), ...
The American Journal of Managed Care

Conduction System Pacing Falls Short of Biventricular Pacing in HFrEF With LBBB

A 173-patient randomized trial in HFrEF (LVEF ≤35%) with LBBB (QRS ≥130 ms) showed CSP was inferior to BiVP for a hierarchical 12‑month composite endpoint. Worse outcomes with CSP were reflected by an ...